SonoScape Medical Corp. (SHE:300633)
China · Delayed Price · Currency is CNY 19.26
-0.69 (-3.46%)
Sep 11, 2026, 3:04 PM CST
SonoScape Medical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 8,136 | 11,356 | 12,656 | 20,370 | 23,460 | 12,833 | |
Market Cap Growth | -47.61% | -10.27% | -37.87% | -13.17% | 82.80% | 22.89% |
Enterprise Value | 7,351 | 10,240 | 11,212 | 18,761 | 22,088 | 12,399 |
Last Close Price | 19.26 | 26.18 | 29.03 | 46.33 | 53.54 | 31.07 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 50.37 | 57.56 | 88.88 | 44.82 | 63.44 | 51.91 |
Forward PE | 27.77 | 33.16 | 25.87 | 34.58 | 57.53 | 50.58 |
PS Ratio | 3.39 | 4.92 | 6.29 | 9.61 | 13.31 | 8.88 |
PB Ratio | 2.70 | 3.48 | 4.07 | 6.48 | 8.56 | 5.45 |
P/TBV Ratio | 2.94 | 3.77 | 4.46 | 7.24 | 9.73 | 6.32 |
P/FCF Ratio | - | - | 126.82 | 65.19 | 82.92 | 85.13 |
P/OCF Ratio | 85.15 | - | 41.27 | 41.62 | 49.57 | 42.36 |
PEG Ratio | - | 1.65 | 1.65 | 2.25 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.07 | 4.43 | 5.57 | 8.85 | 12.53 | 8.58 |
EV/EBITDA Ratio | 31.03 | 53.33 | 66.86 | 36.95 | 61.94 | 50.04 |
EV/EBIT Ratio | 54.85 | 92.03 | 111.05 | 40.99 | 68.81 | 57.35 |
EV/FCF Ratio | - | - | 112.35 | 60.04 | 78.07 | 82.26 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.10 | 0.10 | 0.11 | 0.02 | 0.08 | 0.05 |
Debt / EBITDA Ratio | 1.27 | 1.47 | 1.90 | 0.14 | 0.58 | 0.41 |
Debt / FCF Ratio | - | - | 3.56 | 0.23 | 0.77 | 0.74 |
Net Debt / Equity Ratio | -0.26 | -0.41 | -0.53 | -0.56 | -0.56 | -0.55 |
Net Debt / EBITDA Ratio | -3.54 | -7.05 | -9.87 | -3.45 | -4.31 | -5.26 |
Net Debt / FCF Ratio | 20.40 | 7.11 | -16.58 | -5.61 | -5.43 | -8.65 |
Asset Turnover | 0.59 | 0.53 | 0.50 | 0.58 | 0.54 | 0.55 |
Inventory Turnover | 1.10 | 1.30 | 1.33 | 1.38 | 1.31 | 1.42 |
Quick Ratio | 1.68 | 1.94 | 2.08 | 3.55 | 2.64 | 3.00 |
Current Ratio | 2.98 | 2.76 | 2.75 | 4.62 | 3.36 | 3.84 |
Return on Equity (ROE) | 5.35% | 6.19% | 4.55% | 15.44% | 14.52% | 13.36% |
Return on Assets (ROA) | 2.07% | 1.59% | 1.56% | 7.82% | 6.11% | 5.13% |
Return on Invested Capital (ROIC) | 6.16% | 6.62% | 7.09% | 33.84% | 27.59% | 21.64% |
Return on Capital Employed (ROCE) | 4.10% | 3.30% | 3.10% | 14.30% | 11.50% | 8.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.02% | 1.74% | 1.13% | 2.23% | 1.58% | 1.93% |
FCF Yield | -0.47% | -1.68% | 0.79% | 1.53% | 1.21% | 1.18% |
Dividend Yield | 0.92% | 0.69% | 0.34% | 0.69% | 0.34% | 0.40% |
Payout Ratio | 48.68% | 23.94% | 101.36% | 18.20% | 15.62% | 2.24% |
Buyback Yield / Dilution | 0.76% | 0.61% | 0.30% | -0.65% | -7.83% | -3.44% |
Total Shareholder Return | 1.69% | 1.30% | 0.64% | 0.04% | -7.50% | -3.04% |